Insider buying last 90 days
No open-market insider purchases were filed for JAZZ in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Jazz Pharmaceuticals closed at $243.55 on 9 November 2026, +3.7% on the day. The price sits above both the 50-day ($229.37) and 200-day ($218.47) moving averages, inside a 52-week range of $128.80 to $266.38. The GekkoIndex reads 49.9, in the Neutral zone, down 12.2 points over five sessions. Gekko Fair Value is $324.61, so the price is 25% below it.
The next earnings report is due on 23 February 2027, 100 days away (after close). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 8.1% across the report. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged +5.2% over the last 5 years, rising in 3 of them.
17 firms rate the stock: 16 buy, 1 hold and 0 sell, with a consensus target of $295.50. A typical daily move is about 3.2%, and a typical 20-day move about 4.8%. On the swing-trade checklist, 5 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 9, 2026 close.
Jazz Pharmaceuticals scores 5 supportive, 1 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
5 supportive1 mixed0 headwinds
Above 50 and 200-day
Close $241.55 is above the 50-day ($229.13) and 200-day ($220.03) averages, and the 50-day is above the 200-day.
See the chart51.5, Neutral
Reading 51.5 is in the Neutral zone.
See the GekkoIndex22.2% below
Price is 22.2% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 100 days
Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.
See earnings+1.4% on average
From this point in the calendar, the next 20 trading days averaged +1.4% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Jazz Pharmaceuticals closed at $241.55 on Nov 13, 2026, +76.7% over the past year, inside a 52-week range of $136.56 to $266.38.
Use the left and right arrow keys to read daily values.
Put JAZZ on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Jazz Pharmaceuticals researches, develops, and brings to market medicines sold across the United States, Europe, and other international regions. Its treatments address conditions such as narcolepsy and idiopathic hypersomnia, seizure disorders including Lennox-Gastaut and Dravet syndromes, several forms of leukemia and lymphoma, certain lung and biliary tract cancers, a specific type of glioma, and severe veno-occlusive disease, with products including Xywav, Epidiolex, Rylaze, Enrylaze, Zepzelca, Ziihera, Modeyso, Defitelio, and Vyxeos.
Beyond its marketed products, the company runs a pipeline of experimental treatments at various clinical stages, spanning cancers such as gastroesophageal adenocarcinoma, biliary tract cancer, breast cancer, acute myeloid leukemia, and rare tumor types, along with therapies aimed at glioma and absence epilepsy. It advances some of this work through licensing and collaboration arrangements with other firms, including Redx Pharma, Autifony Therapeutics, Zymeworks, Sumitomo Pharma, and Werewolf Therapeutics.
Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland. Its shares are listed on the NASDAQ under the ticker JAZZ.
Jazz Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51.5, in the Neutral zone, down 1.4 points over five sessions.
Down 1.4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 33 | +0.4% | +2.6% | ||
| Accumulation | 160 | +1.2% | +0.8% | ||
| Neutral (current zone) | 464 | +0.6% | +2.7% | ||
| Distribution | 39 | −1.7% | −1.1% | ||
| Selling | 6 | Too few readings yet | |||
Average JAZZ share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Jazz Pharmaceuticals trades 22.2% below Gekko Fair Value of $310.39, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Jazz Pharmaceuticals shares are worth, recalculated every trading day.
$310.39
Gekko Fair Value, Nov 14, 2026
22.2% Undervalued
At the end of Aug 2026 the price was 23.1% below the estimate.
No open-market insider purchases were filed for Jazz Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for JAZZ in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in JAZZ were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Jazz Pharmaceuticals has been buying back its own shares.
From company filings.
1signal, 100% of the flagged premium in calls.
Latest: Bullish flow on Nov 4, $338K in unusual premium.
1of the funds Gekko tracks holds JAZZ.
Jazz Pharmaceuticals reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 23, 2027
Expected after the close, 100 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 2, 2026 | −$3.88 est −$4.03 | $1.24B est $1.21B | +6.4% |
| Aug 3, 2026 | $4.89 est $5.06 | $1.21B est $1.11B | +3.5% |
| May 5, 2026 | $6.34 est $4.66 | $1.20B est $1.17B | +9.9% |
| Feb 24, 2026 | $6.64 est $6.51 | — | +13.6% |
| Nov 5, 2025 | $8.13 est $5.95 | $1.13B est $1.11B | −2.7% |
| Aug 5, 2025 | −$8.25 est −$6.12 | $1.05B est $1.05B | −8.8% |
| May 6, 2025 | $1.68 est $4.66 | $897.8M est $1.06B | −14.2% |
| Feb 25, 2025 | $6.60 est $5.81 | $1.09B est $985.0M | +5.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Jazz Pharmaceuticals is $296.77, +22.9% from the last close, from 17 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 17 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Morgan Stanley | $324 | +34.1% |
| Nov 12 | Piper Sandler | $330 | +36.6% |
| Nov 3 | Barclays | $275 | +13.8% |
| Nov 3 | RBC Capital | $305 | +26.3% |
| Nov 3 | Wells Fargo | $300 | +24.2% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Jazz Pharmaceuticals averaged +1.4% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.4% | 2 of 5 |
| Next 10 trading days | +0.1% | 2 of 5 |
| Next 15 trading days | +0.7% | 2 of 5 |
| Next 20 trading days | +1.4% | 3 of 5 |
| Next 30 trading days | +3.6% | 2 of 5 |
For scale, JAZZ’s typical 20-trading-day move in either direction is about 4.9%.
Jazz Pharmaceuticals’s market cap is $15.50B, with a P/E ratio of 71.1 and revenue of $4.72B over the last twelve months.
Coverage of Jazz Pharmaceuticals this week reads neutral: 3 positive, 4 neutral and 1 negative headlines.
Jazz Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Jazz Pharmaceuticals’s market cap is $15.50B at the Nov 13, 2026 close of $241.55, with 64.19M shares outstanding. The shares trade on a P/E ratio of 71.1.
The consensus analyst 12-month price target for Jazz Pharmaceuticals is $296.77, +22.9% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Jazz Pharmaceuticals is undervalued: the Nov 13, 2026 close of $241.55 is 22.2% below Gekko Fair Value of $310.39. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Jazz Pharmaceuticals is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of $6.97 per share on revenue of $1.28B. Jazz Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 8.1% on average across the report.
Jazz Pharmaceuticals’s 52-week high is $266.38 and its 52-week low is $136.56; it closed at $241.55 on Nov 13, 2026, +76.7% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 5 of the 6 items with data read as supportive (trend, fair value, smart money, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Jazz Pharmaceuticals over the last 30 days, with $338K of flagged premium in calls and $0 in puts. The latest, bullish flow, was on Nov 4, 2026 with $338K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.